Anti-Inflammatory Drugs Market Report 2026

The anti-inflammatory drugs market size has grown rapidly in recent years. It will grow from $152.08 billion in 2025 to $168.74 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to arthritis prevalence, nsaid usage, hospital prescribing, autoimmune disease burden, steroid therapy adoption.

The anti-inflammatory drugs market size is expected to see rapid growth in the next few years. It will grow to $252.87 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to biologic innovation, biosimilar penetration, aging population, autoimmune disease growth, precision medicine adoption. Major trends in the forecast period include growing use of biologics and biosimilars, expansion of chronic inflammatory disease treatment, shift toward targeted anti-inflammatory therapies, growth of topical and localized formulations, increased focus on long-term safety.

The rising prevalence of arthritis is expected to drive the growth of the anti-inflammatory drugs market in the coming years. Arthritis is the inflammation of one or more joints, causing pain, swelling, and stiffness that often worsens with age. The increasing incidence of arthritis is primarily linked to aging populations, as natural wear and tear on joints over time raises the likelihood of developing the condition. Anti-inflammatory drugs help manage arthritis by reducing joint inflammation and pain, enabling patients to maintain mobility, perform daily activities more easily, and improve overall quality of life. For example, in July 2024, Restored CDC, a US-based nonprofit health information organization, reported that an estimated 21.2% of adults aged 18 and older in the US were diagnosed with arthritis in 2023. Therefore, the rising prevalence of arthritis is fueling growth in the anti-inflammatory drugs market.

Leading companies in the anti-inflammatory drugs market are focusing on innovative solutions, such as next-generation corticosteroid alternatives, to meet the growing demand for safer long-term anti-inflammatory therapies. Next-generation corticosteroid alternatives are designed to retain glucocorticoid anti-inflammatory effects while minimizing adverse outcomes commonly associated with traditional steroids, including bone loss, growth suppression, and weight gain. For instance, in October 2023, Santhera Pharmaceuticals, a Switzerland-based specialty pharmaceutical company, received FDA approval for AGAMREE (vamorolone). AGAMREE is an oral dissociative steroid that delivers anti-inflammatory activity with reduced steroid-related side effects by selectively modulating glucocorticoid receptor pathways and stabilizing cell membranes. Compared to traditional corticosteroids like prednisone and deflazacort, it offers a more favorable safety profile while maintaining therapeutic benefits and is used to manage chronic muscle inflammation in children aged two years and older with Duchenne muscular dystrophy.

In October 2023, Amgen, a US-based biopharmaceutical company, acquired Horizon Therapeutics for approximately $27.8 billion. Through this acquisition, Amgen aims to strengthen its portfolio in autoimmune and severe inflammatory diseases by integrating Horizon’s therapies, including TEPEZZA, KRYSTEXXA, and UPLIZNA, and expanding its presence in the treatment of rare and chronic inflammatory conditions. Horizon Therapeutics is an Ireland-based biopharmaceutical company specializing in therapies for rare inflammatory and autoimmune diseases.

Major companies operating in the anti-inflammatory drugs market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Cadila Pharmaceuticals, Samsung Bioepis, Lupin Limited.

North America was the largest region in the anti-inflammatory drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of APIs, biologics, and formulation excipients in the anti-inflammatory drugs market, raising production and distribution expenses for both NSAIDs and biologic therapies. Biologics, biosimilars, and injectable anti-inflammatory drugs are most impacted, particularly in North America and Europe, which rely heavily on global pharmaceutical supply chains. On the positive side, tariffs are driving local manufacturing investments and biosimilar development, enhancing long-term market competitiveness and supply stability.

The anti-inflammatory drugs market research report is one of a series of new reports that provides anti-inflammatory drugs market statistics, including anti-inflammatory drugs industry global market size, regional shares, competitors with a anti-inflammatory drugs market share, detailed anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory drugs industry. This anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-inflammatory drugs are medications that reduce inflammation, pain, fever, and swelling by modulating the body’s natural inflammatory response. They act by inhibiting the production or activity of chemical messengers such as prostaglandins, leukotrienes, and cytokines, which play key roles in initiating and sustaining inflammation.

The main classes of anti-inflammatory drugs include steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics and biosimilars, and others. Steroids are anti-inflammatory agents that mimic natural hormones and are used to treat conditions such as asthma, arthritis, and allergies. They can be administered via parenteral, oral, topical, and inhalation routes. These drugs are applied in a variety of conditions, including autoimmune diseases, respiratory disorders, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-inflammatory drugs market consists of sales of immunosuppressants, COX-2 inhibitors, interleukin inhibitors, and TNF-alpha inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.